Nath Bio-Genes (India) Ltd

Nath Bio-Genes (India) Ltd - Trading window closed from 01 October 2026 up to 48 hours after the declaration of unaudited financial results for the quarter and half year ending 30 September 2026

AGM details

• 33rd AGM held on 24 September 2026 at 11:00 AM via VC/OAVM.
• Remote e-voting from 21 September 2026, 09:00 AM to 23 September 2026, 5:00 PM.
• Meeting duration 11:00–11:31; quorum present via VC/OAVM.

Resolutions presented

• Adopt audited standalone and consolidated financial statements for year ended 31 March 2026.
• Declare final dividend of ₹2 per equity share.
• Appoint Jeevanlata Kagliwal as director, retires by rotation, eligible for re-appointment.
• Re-appoint Hitesh Purohit as independent director for a second five-year term to 2032.
• Remuneration revision for Managing Director Satish Kagliwal.

Voting results

• Resolutions Nos. 1-5 passed with requisite majority.
• No material dissent reported.

Dividend

• Final dividend of ₹2 per equity share approved.

Director changes

• Jeevanlata Kagliwal appointed director, retires by rotation.
• Hitesh Purohit re-appointed as independent director for second term through 2032.

Scrutinizer

• Neha P. Agrawal appointed as scrutinizer for e-voting.

Other material approvals

• No material related party transactions disclosed.

Forensic audit mandate

• SEBI appointed CNK & Associates LLP as forensic auditor for Nath Bio-Genes India.
• The forensic audit covers financial years 2020-21 to 2025-26.
• Nath Bio-Genes will provide information and access as required.
• Company will not comment further pending completion of the audit.

Q1FY27 Highlights

• Q1FY27 unaudited results presentation for period ended 30 June 2026.
• Revenue for Q1FY27 ₹3,228 million, up 15% YoY.
• Gross profit ₹1,629 million; gross margin 50%.
• EBITDA ₹351 million; EBITDA margin 11%.
• PBT after adjustment of exceptional items ₹334 million; tax ₹7 million; PAT ₹327 million.
• Earnings per share ₹17.18; YoY up 12%.
• Q1FY27 revenue mix: Paddy 35%, Cotton 34%, Others 31%.
• FY26 full-year: Revenue ₹4,316 million; EBITDA ₹525 million.
• Balance sheet notes indicate a strong balance sheet with maintained profitability.

Meeting Details

• Board meeting on 29 July 2026 to approve unaudited results (standalone and consolidated) ended 30 June 2026.

Key Agenda Items

• To consider and approve unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.
• To transact any other business with the permission of the Chair.

Other Notes

• Trading window closure period noted; dates not specified in this summary.